BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22889774)

  • 1. Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.
    Enslow MS; Zollinger LV; Morton KA; Butterfield RI; Kadrmas DJ; Christian PE; Boucher KM; Heilbrun ME; Jensen RL; Hoffman JM
    Clin Nucl Med; 2012 Sep; 37(9):854-61. PubMed ID: 22889774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis.
    Takenaka S; Asano Y; Shinoda J; Nomura Y; Yonezawa S; Miwa K; Yano H; Iwama T
    Neurol Med Chir (Tokyo); 2014; 54(4):280-9. PubMed ID: 24305028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of 3'-deoxy-3'-18F-fluorothymidine ([(18)F] FLT PET) in patients with recurrent malignant gliomas.
    Zhao F; Cui Y; Li M; Fu Z; Chen Z; Kong L; Yang G; Yu J
    Nucl Med Biol; 2014 Sep; 41(8):710-5. PubMed ID: 24929963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma.
    Wondergem MJ; Rizvi SN; Jauw Y; Hoekstra OS; Hoetjes N; van de Ven PM; Boellaard R; Chamuleau ME; Cillessen SA; Regelink JC; Zweegman S; Zijlstra JM
    J Nucl Med; 2015 Feb; 56(2):216-21. PubMed ID: 25593118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
    Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
    Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous
    Jena A; Taneja S; Jha A; Damesha NK; Negi P; Jadhav GK; Verma SM; Sogani SK
    AJNR Am J Neuroradiol; 2017 May; 38(5):899-907. PubMed ID: 28341716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeatability of
    Lodge MA; Holdhoff M; Leal JP; Bag AK; Nabors LB; Mintz A; Lesser GJ; Mankoff DA; Desai AS; Mountz JM; Lieberman FS; Fisher JD; Desideri S; Ye X; Grossman SA; Schiff D; Wahl RL
    J Nucl Med; 2017 Mar; 58(3):393-398. PubMed ID: 27688473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among
    Tomura N; Kokubun M; Saginoya T; Mizuno Y; Kikuchi Y
    AJNR Am J Neuroradiol; 2017 Aug; 38(8):1520-1527. PubMed ID: 28619837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of
    He Q; Zhang L; Zhang B; Shi X; Yi C; Zhang X
    BMC Cancer; 2019 Apr; 19(1):332. PubMed ID: 30961564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma.
    Tsuyuguchi N; Takami T; Sunada I; Iwai Y; Yamanaka K; Tanaka K; Nishikawa M; Ohata K; Torii K; Morino M; Nishio A; Hara M
    Ann Nucl Med; 2004 Jun; 18(4):291-6. PubMed ID: 15359921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
    Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
    Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring spatial overlap of high-uptake regions derived from dual tracer positron emission tomography-computer tomography imaging using 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine in nonsmall cell lung cancer patients: a prospective pilot study.
    Liu J; Li C; Hu M; Lu J; Shi X; Xing L; Sun X; Fu Z; Yu J; Meng X
    Medicine (Baltimore); 2015 May; 94(17):e678. PubMed ID: 25929896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
    Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
    J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera--a pilot study.
    Stokkel M; Stevens H; Taphoorn M; Van Rijk P
    Nucl Med Commun; 1999 May; 20(5):411-7. PubMed ID: 10404525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis comparing 18F-FLT PET with 18F-FDG PET for assessment of brain tumor recurrence.
    Li Z; Yu Y; Zhang H; Xu G; Chen L
    Nucl Med Commun; 2015 Jul; 36(7):695-701. PubMed ID: 25768337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential for differentiation of glioma recurrence from radionecrosis using integrated
    Sogani SK; Jena A; Taneja S; Gambhir A; Mishra AK; D'Souza MM; Verma SM; Hazari PP; Negi P; Jadhav GK
    Neurol India; 2017; 65(2):293-301. PubMed ID: 28290392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
    Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
    J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.
    Spence AM; Muzi M; Link JM; O'Sullivan F; Eary JF; Hoffman JM; Shankar LK; Krohn KA
    Mol Imaging Biol; 2009; 11(5):343-55. PubMed ID: 19326172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging.
    Ozsunar Y; Mullins ME; Kwong K; Hochberg FH; Ament C; Schaefer PW; Gonzalez RG; Lev MH
    Acad Radiol; 2010 Mar; 17(3):282-90. PubMed ID: 20060750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.